The sales appear to be part of a pre-arranged 10b5-1 plan or tax-driven exercise of vested options rather than a signal of fundamental concern. Traders should monitor for any changes in forward guidance or corporate strategy, but this cluster is consistent with routine insider activity for a company of this size.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 17 $540.02entry
- T+1 · 8mo ago −1.79%α −0.40% · $530.35
- T+5 · 8mo ago −1.52%α +1.11% · $531.82
- T+20 · 7mo ago +6.96%α +2.61% · $577.58
- T+60 · 5mo ago +1.00%α −8.99% · $545.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics CEO Martine Rothblatt and other insiders engaged in a series of derivative exercises and open-market sales over the past week, generating $2.8 million in total proceeds from stock sales. The activity is primarily tied to option exercises and tax-related sales, with the CEO accounting for the majority of transactions.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt exercised options for 95,000 shares across multiple days (10 tranches of 9,500 shares), with 5 tranches at $146.03 (total value $6.94M) and 5 at $0 (non-cash).
- Rothblatt sold 852 shares in open-market transactions totaling $447,085.17 at prices between $520.34 and $531.21.
- EVP Paul Mahon exercised options for 16,600 shares at $146.03 (value $2.42M) and sold 753 shares for $397,183.86.
- Director Jan Malcolm sold 45 shares for $24,007.95.
- Total open-market sales in the cluster: $868,277.01 across 1,649 shares.
- All derivative exercises were at a strike price of $146.03 or $0, suggesting expiration or vesting of long-held options.
Financial Impact
$868,277 in open-market sales and $9.36M in derivative exercises (mostly non-cash or tax-related)
Risk Factors
- Perception of insider selling could weigh on sentiment despite being routine.
- Future large-scale option exercises could lead to sustained selling pressure if used for liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (16 trades, 7d window) | cluster-UTHR-1774297898268 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers